Monday Morning Movers

Conatus Pharmaceuticals Inc CNAT +40% - The company announced plans to report top-line results of its clinical trials of Emricasan on January 8th.

Cempra Inc. CEMP +12% - On Sunday, the company announced positive results from its pneumonia study; meeting primary and secondary objectives.

Immunomedics Inc. IMMU +7% - Shares are higher after the company won fast track designation for its IMMU-132 drug.

Cerus Corporation CERS +5.1% - The company announced that its EU Phase 3 trial of INTERCEPT met primary endpoint.

ISIS Pharmaceuticals Inc. ISIS +3.7% - The company announced a deal with Johnson & Johnson’s Janssen Biotech Inc.

El Pollo LoCo Holdings Inc. LOCO +3.2% - Analysts at Baird upgraded shares of El Pollo Loco to Outperform.

Brainstorm Cell Therapeutics BCLI -8% - Shares are lower following the company’s announcement of its final analysis of its phase 2a ALS study.

Starbucks Corporation SBUX -1.4% - On Monday, analysts at Janney Capital downgraded Starbucks shares to Neutral and lowered the price target to $85.

Amgen Inc AMGN -1.1% - Shares were downgraded to Equal-weight at Morgan Stanley.